Innovations
Commented by André Will-Laudien on June 24th, 2026 | 08:45 CEST
AI and Chip Sell-Off! Watch Out for SMCI, AMD, and Infineon; First Hydrogen in the Innovation Race
The stock market is currently showing no mercy. After months of gains in AI, high-tech, and chip stocks, the market has now shifted into profit-taking mode—and, at times, even sell-off mode. What analysts have been predicting for quite some time is increasingly coming to pass. The global stock market rally, driven by the NASDAQ, is taking its toll. While the long-term earnings outlook may be solid, short-term price surges of up to 2,000% in just 12 months no longer indicate a healthy market trend. So, while it comes as no surprise, it may be unwelcome for many market participants: a sharper downward move—one that, however, also brings new opportunities in its wake. We examine the fundamental framework of the key players and highlight alternatives for getting off to an innovative start today. The stock market keeps turning—just a little slower at times!
Read
Commented by Tarik Dede on June 24th, 2026 | 08:05 CEST
Innovation in Research: Opportunities at Vertex Pharmaceuticals, BioNxt Solutions, and BioNTech
On social media, you can find all sorts of negative comments and memes about the Pfizer Corporation. One very popular one claims that the company—founded in New York by German immigrants (Karl Pfizer and Karl Erhart)—has never cured a single disease in its 177-year history. This is at least partly true, as Pfizer—particularly for chronic, widespread conditions like high blood pressure or high cholesterol—focuses on treating symptoms rather than the underlying causes. However, it is also true that during World War II, Pfizer was the world's first and largest mass producer of penicillin. Critics level this same accusation against many pharmaceutical companies. Nevertheless, there are numerous companies working on innovative approaches to truly defeat diseases and improve people's lives. And, of course, they also aim to make a lot of money in the process. That is why we are taking a look today at the stocks of Vertex Pharmaceuticals, BioNxt Solutions, and BioNTech.
Read
Commented by Nico Popp on June 18th, 2026 | 07:35 CEST
The Secret Mechanism That Kills Cancer Cells: What Revolution Medicines and Merck & Co. Need to Learn from Vidac Pharma
There is, without exaggeration, a looming "patent cliff" of enormous scale: an estimated USD 236 billion in annual revenue losses are forcing the biopharmaceutical industry to find new paths forward. Pharma giants must replace dwindling blockbuster revenues by strategically acquiring innovative oncology platforms, as conventional cancer therapies are increasingly reaching their limits. This innovation pressure is triggering a consolidation wave in which research-driven biotech companies with protected mechanisms of action are moving into the center of potential takeover activity. In particular, intracellular and metabolic treatment approaches are rapidly gaining importance in the fight against treatment-resistant cancers. We take a look at Revolution Medicines' successes and identify the next potential high-flyer.
Read
Commented by Stefan Feulner on June 15th, 2026 | 07:40 CEST
Nurix, BioNxt Solutions, Zealand Pharma: New Therapies Ignite the Imagination
The biotech sector is currently experiencing tremendous momentum. Therapies for obesity, diabetes, autoimmune diseases, and neurological conditions, in particular, rank among the largest growth markets in the healthcare industry. The booming GLP-1 market for weight loss and metabolic disorders alone is expected to reach a volume of tens of billions of USD in the coming years. At the same time, new classes of active ingredients and innovative delivery technologies are providing fresh momentum. Investors find themselves in an environment where clinical advances and technological innovations can trigger significant increases in value.
Read
Commented by Carsten Mainitz on April 10th, 2026 | 08:20 CEST
Unlocking Massive Potential in Pharma's Largest Segment: Innovator Vidac Pharma, Industry Leader Bayer, or Turnaround Candidate Evotec?
Oncology is the most strategically important growth market in the pharmaceutical industry and at the same time one of the key levers for improving global health. Currently, around 20 million people worldwide are diagnosed with cancer each year, a figure expected to exceed 30 million annually by 2040. The global oncology drug market is already valued at over USD 200 billion and continues to expand rapidly. Bayer aims to rank among the world's leading oncology players by 2030 and recently reaffirmed its medium-term targets. Following the sale of a stake in a cancer specialist, shareholders of Evotec, which has faced significant pressure, may soon benefit from a welcome inflow of funds. Vidac Pharma, on the other hand, is breaking new ground in the fight against skin cancer. There is enormous potential here.
Read
Commented by Nico Popp on March 30th, 2026 | 08:30 CEST
A Paradigm Shift in Oncology: Core Stocks Roche & Galderma and the High-Leverage Opportunity in Vidac Pharma
Medical advances affect us all. Oncology is also undergoing a transformation. As conventional immunotherapies for skin cancer increasingly reach their limits, clinical research is shifting its focus to correcting defective tumor metabolism. The Warburg effect, where cancer cells shift energy production to aerobic glycolysis to fuel uncontrolled growth, offers a promising entry point. This dynamic development landscape is exacerbated by an impending patent cliff, which, according to calculations by the consulting firm PwC, threatens industry revenues of USD 104 billion by 2028, as many patents for active ingredients are expiring. Currently, market researchers at Fortune Business Insights estimate the volume of the global oncology market for 2026 at USD 286.36 billion. While pharmaceutical giant Roche secures its market leadership and the Galderma Group dominates standard dermatological care, biotechnology company Vidac Pharma is targeting the metabolic vulnerability of cancer cells with a completely novel mechanism of action, aiming to effectively shut down the cancer.
Read
Commented by Mario Hose on February 27th, 2026 | 07:05 CET
Revolution in cancer therapy: Vidac Pharma attacks the cancer throne of the big players! Why the smaller competitor could steal the show from giants like Bayer and BioNTech!
The world of biotechnology and pharmaceuticals is currently in turmoil, as technological breakthroughs and strategic realignments promise an exciting future for investors. The focus is particularly on Vidac Pharma, an innovative company that wants to revolutionize the fight against cancer with a completely new approach to oncology and is currently celebrating one milestone after another. While Vidac Pharma shines with impressive clinical progress and strong internal backing from its main shareholder, Dr. Max Herzberg, industry giant Bayer has recently struggled with the late effects of the Monsanto acquisition, but is now increasingly being touted as an exciting candidate for a split or takeover by financial investors. At the same time, BioNTech remains synonymous with cutting-edge mRNA technology, with the market eagerly awaiting the next phase after the pandemic. In this dynamic environment, Vidac Pharma is emerging as a particularly bright star in the biopharmaceutical sky, causing a sensation with its unique method of specifically normalizing the metabolism of cancer cells.
Read
Commented by André Will-Laudien on February 4th, 2026 | 07:10 CET
Starting signal! Biotech sector benefits from rotation! Keep an eye on Evotec, Bayer, Vidac Pharma, and BioNTech
The stock market has started 2026 on a positive note. The mining and commodities sector recently proved that return opportunities are not limited to the technology sector, with several stocks doubling in price and a few even increasing tenfold. A breath of fresh air is needed, because other sectors also want to enjoy the stock market spring. Life science stocks have indeed taken a break for almost three years. But now they are back! After a long period of silence, selected companies are showing the first signs of a technical recovery. For investors with a penchant for opportunities and timing, now is the time to rethink old strategies and realign portfolios. In cancer research, recent breakthroughs in personalized immunotherapies have significantly increased the prospects of success for clinical trials. We take a closer look.
Read
Commented by André Will-Laudien on January 2nd, 2026 | 07:05 CET
Attention - fasten your seatbelts! 2026 could be a rocket launch for Novo Nordisk, Evotec, Bayer, and Vidac Pharma
The stock market is starting the new year 2026 in a buoyant mood. The mining and commodities sector showed that it is not only possible to make money with tech stocks, with almost every stock doubling in value, and some even increasing tenfold. The coming year, however, could bring yet another shift in perspective. The biotech sector has been quiet for quite some time, but some of the protagonists in our selection are showing, in part, significant technical base formations. For risk-aware investors, it may be time to reshuffle more decisively and realign portfolios. Come in and find out!
Read
Commented by Nico Popp on December 9th, 2025 | 07:05 CET
Attacking the fuel that feeds tumors: Why Roche, Pfizer, and Vidac Pharma are redefining oncology
Modern cancer therapy is no longer about blunt-force attacks, but rather precise, targeted interventions. While oncology in recent decades has been dominated by non-specific cell toxins, today's research resembles surgical intervention in the biological software of a disease. Industry heavyweights, Roche and Pfizer, are securing their market positions with gigantic portfolios of immunotherapies. But away from the corporate headquarters of Basel and New York, agile biotech pioneers are working on approaches that attack the very foundation of cancer cells: their energy supply. Those who pull the plug on cancer cells could be among the big winners in the biotech sector in 2026.
Read